What we do?
Clinical Professor, Department of Clinical Oncology, The University of Hong Kong Chief of Service, Oncology Medical Center, the University of Hong Kong-Shenzhen Hospital Deputy Hospital Chief Executive (Clinical affairs), the University of Hong Kong-Shenzhen Hospital
Since the establishment of megavoltage radiotherapy in Hong Kong by Professor John HC Ho, all local oncologists have been trying hard to save the lives of patients with nasopharyngeal cancer, a cancer with peculiarly high prevalence among Southern Chinese. All along, local colleagues are dedicated not only to clinical services, but also to researches at individual centers for better understanding of this unique cancer and continual improvement of survival. Our achievements are internationally well-recognized.
The concept of forming a multi-center Study Group was initiated following the publication of the Intergroup-0099 Study which showed significant survival benefit by addition of cisplatin in concurrence with radical radiotherapy followed by adjuvant chemotherapy using cisplatin-fluorouracil. This was a practice-changing landmark study, but there are serious concerns in prevalent Asian countries whether the magnitude of reported benefit is reproducible and the tolerance for our patients. All colleagues feel the urgent need to re-confirm the therapeutic benefit, through multi-center randomized control trials, before recommending the treatment regimen to our patients.
The Hong Kong Nasopharyngeal Cancer Study Group (HKNPCSG), with participation by all five existing Clinical Oncology Centers, was hence established in 1999.
The Hong Kong Nasopharyngeal CancerThe objects are:
(a) To promote interest in the knowledge of nasopharyngeal cancer.
(b) To facilitate research for improving the knowledge of nasopharyngeal cancer.
(c) To endeavor to improve the standard of care for patients with nasopharyngeal cancer.
To achieve these main objects, the Study Group is committed:
(a)To conduct multi-center clinical studies, including randomized control trials and observational studies (both retrospective and prospective).
(b)To raise funds and obtain sponsorship for supporting researches. Study Group (HKNPCSG), with participation by all five existing Clinical Oncology Centers, was hence established in 1999.